SPRAVATO™ nasal spray is a different kind of medication taken with an oral antidepressant for adults with treatment-resistant depression – a first in decades approved by the FDA.
SPRAVATO™ is used to treat adults with treatment-resistant depression.
Yes. On March 5, 2019, esketamine CIII nasal spray (Spravato; Janssen Pharmaceuticals) was approved by the US Food and Drug Administration (FDA), in conjunction with an oral antidepressant, for the treatment of adults with treatment-resistant depression.